TOP TIERMARKET NEWSWIRE
News & sentiment

BIOCRYST PHARMACEUTI (BCRX) — News & AI sentiment

BIOCRYST PHARMACEUTI (BCRX) news roundup. 1 story in the past week, 10 over 30 days. Average 30-day sentiment is 66.9/100. No insider transactions filed in the last 90 days. US House Periodic Transaction Reports (90-day window): 2 purchases (~$16K) and 0 sales (~$0). Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
1
avg sentiment 78/100
30d stories
10
avg sentiment 66.9/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
2
2 buys · 0 sells

BCRX news in the last 24 hours, 7 days, 30 days and 90 days

How much BCRX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowBCRX storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days178/100BCRX headlines →
Last 30 days1066.9/100BCRX headlines →
Last 90 days4760.3/100BCRX headlines →

Latest stories on BCRX

Oct 21
Oct 21
BioCryst wins FDA nod for Orladeyo oral pellets
Seeking Alpha74 · bullishproduct/pr
Oct 21
Oct 21
Oct 21
Oct 21
Oct 21
Oct 5
Oct 5
Sep 30
Sep 28
Sep 23
Sep 21
Sep 17
Sep 15
Sep 11
Sep 10
Sep 10
Sep 9
Sep 8
Sep 8
Sep 8
TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook
Investing.com Analyst Ratings61 · neutralanalyst
Sep 8
Sep 6
Sep 1
Open BCRX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →